These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 23980667)

  • 1. A Clinical Case of Timely Diagnosis and Successful Treatment of Budd-Chiari Syndrome With Fulminant Cytolysis in the Setting of a First-time Diagnosed Myeloproliferative Disease.
    Husieva SA; Osyodlo GV; Husiev AV; Savichan KV
    Mil Med; 2024 Jun; ():. PubMed ID: 38935394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budd-Chiari syndrome on background of JAK2V617F mutation with no hematologic abnormalities.
    Bint I Bilal A; Ata F; Abdelrazek M; Yassin MA
    Clin Case Rep; 2021 Sep; 9(9):e04668. PubMed ID: 34532043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and validation of a prediction model for the first recurrence of Budd-Chiari syndrome after endovascular treatment: a large sample size, single-center retrospective study.
    Wang Z; Wang Z; Zhang Z; Li J; Pan Z; Liu A; Lu J; Guo J; Zu M; Xu H
    Hepatol Int; 2023 Feb; 17(1):159-169. PubMed ID: 36567373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Contribution of
    Paes J; Silva GAV; Tarragô AM; Mourão LPS
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Budd-Chiari Syndrome.
    Zu M; Xu H; Zhang Q; Gu Y; Wei N; Xu W; Cui Y; Liu H
    J Interv Med; 2020 May; 3(2):65-76. PubMed ID: 34805910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).
    Shukla A; Shreshtha A; Mukund A; Bihari C; Eapen CE; Han G; Deshmukh H; Cua IHY; Lesmana CRA; Al Meshtab M; Kage M; Chaiteeraki R; Treeprasertsuk S; Giri S; Punamiya S; Paradis V; Qi X; Sugawara Y; Abbas Z; Sarin SK
    Hepatol Int; 2021 Jun; 15(3):531-567. PubMed ID: 34240318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological Characteristics and Etiology of Budd-Chiari Syndrome in Upper Egypt.
    Abdel Hameed MR; Elbeih EAS; Abd El-Aziz HM; Afifi OA; Khalaf LMR; Ali Abu Rahma MZ; Sabry A
    J Blood Med; 2020; 11():515-524. PubMed ID: 33408545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budd-Chiari syndrome/hepatic venous outflow tract obstruction.
    Valla DC
    Hepatol Int; 2018 Feb; 12(Suppl 1):168-180. PubMed ID: 28685257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNA profile in patients with membranous obstruction of the inferior vena cava.
    Sun GX; Su Y; Li Y; Zhang YF; Xu LC; Zu MH; Huang SP; Zhang JP; Lu ZJ
    Exp Ther Med; 2016 Mar; 11(3):811-817. PubMed ID: 26997997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic Venous Diseases of the Liver.
    Sabol TP; Molina M; Wu GY
    J Clin Transl Hepatol; 2015 Sep; 3(3):189-94. PubMed ID: 26623265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China.
    Zhang P; Zhang Y; Zhang J; Wang H; Ma H; Wang W; Gao X; Xu H; Lu Z
    Gastroenterol Res Pract; 2015; 2015():807865. PubMed ID: 26557140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budd-Chiari Syndrome in China: A Systematic Analysis of Epidemiological Features Based on the Chinese Literature Survey.
    Zhang W; Qi X; Zhang X; Su H; Zhong H; Shi J; Xu K
    Gastroenterol Res Pract; 2015; 2015():738548. PubMed ID: 26504461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budd-Chiari syndrome and liver transplantation.
    Akamatsu N; Sugawara Y; Kokudo N
    Intractable Rare Dis Res; 2015 Feb; 4(1):24-32. PubMed ID: 25674385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research status of Budd-Chiari syndrome in China.
    Dang X; Li L; Xu P
    Int J Clin Exp Med; 2014; 7(12):4646-52. PubMed ID: 25663961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of treatment modalities for Budd-Chiari Syndrome in China: a preliminary survey of published literature.
    Qi XS; Ren WR; Fan DM; Han GH
    World J Gastroenterol; 2014 Aug; 20(30):10628-36. PubMed ID: 25132785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Budd-Chiari syndrome associated with factor V Leiden and G20210A prothrombin mutation: a meta-analysis.
    Zhang P; Zhang J; Sun G; Gao X; Wang H; Yan W; Xu H; Zu M; Ma H; Wang W; Lu Z
    PLoS One; 2014; 9(4):e95719. PubMed ID: 24755609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
    Wang H; Sun G; Zhang P; Zhang J; Gui E; Zu M; Jia E; Xu H; Xu L; Zhang J; Lu Z
    J Gastroenterol Hepatol; 2014 Jan; 29(1):208-14. PubMed ID: 23980667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
    Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
    Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.